-
公开(公告)号:US20240116850A1
公开(公告)日:2024-04-11
申请号:US18269168
申请日:2021-12-23
申请人: The Broad Institute, Inc. , Instituto Carlos Slim de la Salud, A.C. , The Brigham and Women's Hospital, Inc.
IPC分类号: C07C211/38 , C07C205/05 , C07C209/34 , C07C209/40 , C07C233/06 , C07C271/24 , C07C311/20 , C07D209/48 , C07D333/20
CPC分类号: C07C211/38 , C07C205/05 , C07C209/34 , C07C209/40 , C07C233/06 , C07C271/24 , C07C311/20 , C07D209/48 , C07D333/20 , C07B2200/07 , C07B2200/13 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/42
摘要: The present disclosure relates to compositions and methods related to bicyclo[2.2.1]heptanamine-containing compounds and salts thereof.
-
2.
公开(公告)号:US20220242815A1
公开(公告)日:2022-08-04
申请号:US17560997
申请日:2021-12-23
申请人: The Broad Institute, Inc. , Instituto Carlos Slim de la Salud, A.C. , The Brigham and Women's Hospital, Inc.
发明人: Brian T. Chamberlain , David Kornfilt , Florence F. Wagner , Maria Alimova , Anna Greka , Joseph Growney
IPC分类号: C07C211/38 , A61P13/12 , C07D311/96 , C07C217/52 , C07C209/22 , C07D295/185 , C07C215/44 , C07C229/50
摘要: The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.
-
3.
公开(公告)号:US11840495B2
公开(公告)日:2023-12-12
申请号:US17560997
申请日:2021-12-23
申请人: The Broad Institute, Inc. , Instituto Carlos Slim de la Salud, A.C. , The Brigham and Women's Hospital, Inc.
发明人: Brian T. Chamberlain , David Kornfilt , Florence F. Wagner , Maria Alimova , Anna Greka , Joseph Growney
IPC分类号: C07C211/38 , A61P13/12 , C07C209/22 , C07C215/44 , C07C217/52 , C07C229/50 , C07D295/185 , C07D311/96
CPC分类号: C07C211/38 , A61P13/12 , C07C209/22 , C07C215/44 , C07C217/52 , C07C229/50 , C07D295/185 , C07D311/96 , C07C2602/42 , C07C2603/97 , C07C2603/98
摘要: The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.
-
公开(公告)号:US09266822B2
公开(公告)日:2016-02-23
申请号:US14213679
申请日:2014-03-14
IPC分类号: C07C237/40 , A61K31/167 , C07C233/80 , C07C231/12
CPC分类号: C07C233/80 , A61K31/167 , C07B2200/13 , C07C231/12 , C07C237/42
摘要: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Form B, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Form B, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.
摘要翻译: 公开了新型固体形式的tacedinaline(4-(乙酰氨基)-N-(2-氨基苯基)苯甲酰胺),包括结晶的tacedinaline B型,一种新型结晶的tacedineine TFA盐和无定形tacedinaline。 还公开了包含结晶泼尼松碱B型,新型结晶哌啶胺TFA盐和/或无定形tastroartine的药物组合物,以及通过施用这些新型固体形式治疗各种病症的方法。
-
5.FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY 有权
标题翻译: 用于测定LYSINE修饰酶活性的荧光底物公开(公告)号:US20140335550A1
公开(公告)日:2014-11-13
申请号:US14267276
申请日:2014-05-01
CPC分类号: C12Q1/34 , C07D311/82 , C07K5/10 , C07K7/06 , C09K11/06 , C09K2211/1007 , C09K2211/1088 , C12Q1/37 , G01N2333/98
摘要: The invention relates to a compound of Formula I: F1-X1-L1-X2-P1-X3-G1 (Formula I).
摘要翻译: 本发明涉及式I化合物:F1-X1-L1-X2-P1-X3-G1(式Ⅰ)。
-
公开(公告)号:US20180155760A1
公开(公告)日:2018-06-07
申请号:US15831752
申请日:2017-12-05
CPC分类号: C12Q1/34 , C07D311/82 , C07K5/10 , C07K7/06 , C09K11/06 , C09K2211/1007 , C09K2211/1088 , C12Q1/37 , G01N2333/98
摘要: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1 (Formula I).
-
公开(公告)号:US09856509B2
公开(公告)日:2018-01-02
申请号:US14267276
申请日:2014-05-01
CPC分类号: C12Q1/34 , C07D311/82 , C07K5/10 , C07K7/06 , C09K11/06 , C09K2211/1007 , C09K2211/1088 , C12Q1/37 , G01N2333/98
摘要: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1 (Formula I).
-
公开(公告)号:US20140275268A1
公开(公告)日:2014-09-18
申请号:US14213679
申请日:2014-03-14
IPC分类号: C07C233/80 , C07C231/12
CPC分类号: C07C233/80 , A61K31/167 , C07B2200/13 , C07C231/12 , C07C237/42
摘要: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Form B, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Form B, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.
摘要翻译: 公开了新型固体形式的tacedinaline(4-(乙酰氨基)-N-(2-氨基苯基)苯甲酰胺),包括结晶的tacedinaline B型,一种新型结晶的tacedineine TFA盐和无定形tacedinaline。 还公开了包含结晶泼尼松碱B型,新型结晶哌啶胺TFA盐和/或无定形tastroartine的药物组合物,以及通过施用这些新型固体形式治疗各种病症的方法。
-
-
-
-
-
-
-